Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities researchers at B. Riley issued their Q1 2026 earnings estimates for Orchestra BioMed in a research report issued on Thursday, April 3rd. B. Riley analyst A. Schock expects that the company will post earnings of ($0.54) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.66) per share. B. Riley also issued estimates for Orchestra BioMed's Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.76) EPS.
OBIO has been the topic of several other reports. Barclays assumed coverage on shares of Orchestra BioMed in a research note on Thursday, January 2nd. They set an "overweight" rating and a $16.00 target price on the stock. Chardan Capital restated a "buy" rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Tuesday, April 1st. HC Wainwright decreased their price objective on shares of Orchestra BioMed from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, April 4th. Finally, BTIG Research began coverage on shares of Orchestra BioMed in a report on Thursday, March 20th. They issued a "buy" rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $15.00.
View Our Latest Report on Orchestra BioMed
Orchestra BioMed Stock Up 14.6 %
OBIO stock traded up $0.38 during mid-day trading on Monday, hitting $2.98. 73,724 shares of the company were exchanged, compared to its average volume of 85,885. Orchestra BioMed has a 12-month low of $2.49 and a 12-month high of $8.87. The business has a fifty day simple moving average of $4.33 and a 200-day simple moving average of $5.00. The firm has a market capitalization of $114.17 million, a P/E ratio of -1.85 and a beta of 0.62.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.79 million. Orchestra BioMed had a negative return on equity of 107.04% and a negative net margin of 2,179.33%.
Hedge Funds Weigh In On Orchestra BioMed
Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its holdings in Orchestra BioMed by 26.0% during the 4th quarter. SG Americas Securities LLC now owns 12,785 shares of the company's stock valued at $51,000 after purchasing an additional 2,642 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Orchestra BioMed by 43.6% in the fourth quarter. Wells Fargo & Company MN now owns 13,156 shares of the company's stock worth $53,000 after acquiring an additional 3,992 shares during the last quarter. Millennium Management LLC acquired a new position in Orchestra BioMed during the 4th quarter valued at approximately $86,000. Bank of America Corp DE increased its holdings in shares of Orchestra BioMed by 42.0% in the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company's stock worth $95,000 after acquiring an additional 7,036 shares during the period. Finally, Barclays PLC grew its holdings in Orchestra BioMed by 281.3% in the 3rd quarter. Barclays PLC now owns 31,785 shares of the company's stock worth $163,000 after buying an additional 23,448 shares in the last quarter. Institutional investors and hedge funds own 53.55% of the company's stock.
About Orchestra BioMed
(
Get Free Report)
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
See Also
Before you consider Orchestra BioMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.
While Orchestra BioMed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
